Haemonetics 2nd Quarter and 1st Half Fiscal 2018 Earnings Release Available on Investor Relations Website
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Haemonetics (HAE) PT Raised to $59 at Jefferies; Reiterates Buy
November 8, 2017 9:08 AM ESTJefferies raised its price target on Haemonetics (NYSE: HAE) to $59.00 (from $48.00) while maintaining a Buy rating. The upgrade cycle for NexSys appears underway with several customers launching trials in September while full market release mid-next year assumes new contracts are in place.
The... More
